AURIGENE TO SEPARATE ITS DISCOVERY SERVICES BUSINESS
Aurigene is in the process of separating its Discovery Services Business. More details of the same will be shared in the near future.
The proprietary pipeline comprises:
RORγt (Phase II initiated)
Immuno-oncology: several first-in-class small molecule inhibitors
Transcription inhibitors and precision oncology
Targeted protein degradation for oncology
For additional details contact firstname.lastname@example.org